JP2018507252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507252A5 JP2018507252A5 JP2017558359A JP2017558359A JP2018507252A5 JP 2018507252 A5 JP2018507252 A5 JP 2018507252A5 JP 2017558359 A JP2017558359 A JP 2017558359A JP 2017558359 A JP2017558359 A JP 2017558359A JP 2018507252 A5 JP2018507252 A5 JP 2018507252A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension according
- suspension
- ophthalmic
- active ingredient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000725 suspension Substances 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940100654 ophthalmic suspension Drugs 0.000 claims 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229960004875 difluprednate Drugs 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 2
- 229950009769 etabonate Drugs 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 229950005134 polycarbophil Drugs 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 1
- 229960003744 loteprednol etabonate Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107696P | 2015-01-26 | 2015-01-26 | |
| US62/107,696 | 2015-01-26 | ||
| PCT/US2016/014872 WO2016123079A1 (en) | 2015-01-26 | 2016-01-26 | Ophthalmic suspension composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507252A JP2018507252A (ja) | 2018-03-15 |
| JP2018507252A5 true JP2018507252A5 (enExample) | 2019-03-07 |
Family
ID=55359733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558359A Pending JP2018507252A (ja) | 2015-01-26 | 2016-01-26 | 眼用懸濁組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10596107B2 (enExample) |
| EP (5) | EP3470059B1 (enExample) |
| JP (1) | JP2018507252A (enExample) |
| KR (1) | KR102538370B1 (enExample) |
| CN (1) | CN107427464B (enExample) |
| AU (4) | AU2016211745A1 (enExample) |
| BR (1) | BR112017016016B1 (enExample) |
| CA (1) | CA2975106A1 (enExample) |
| ES (5) | ES2966595T3 (enExample) |
| HU (5) | HUE071679T2 (enExample) |
| MX (1) | MX390671B (enExample) |
| PL (5) | PL3721868T5 (enExample) |
| PT (3) | PT4268850T (enExample) |
| SI (1) | SI4268850T1 (enExample) |
| WO (1) | WO2016123079A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470059B1 (en) | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
| CA3001955C (en) | 2015-10-16 | 2023-11-28 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of difluprednate |
| EP3245988B1 (en) | 2016-05-18 | 2023-12-27 | Sonikure Holdings Limited | System for ultrasound-enhanced transscleral delivery of drugs |
| US11344562B2 (en) | 2017-08-15 | 2022-05-31 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| EP3853317A4 (en) * | 2018-09-21 | 2022-06-22 | PS Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| EP4431497A1 (en) * | 2019-02-15 | 2024-09-18 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| US20230172946A1 (en) * | 2019-08-18 | 2023-06-08 | Iview Therapeutics, Inc. | In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate |
| KR102271247B1 (ko) * | 2020-11-04 | 2021-06-30 | 삼천당제약주식회사 | 안과용 현탁액 조성물의 제조방법 |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| EP0163696B1 (en) | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| IE63392B1 (en) | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| CA2134376C (en) | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| AU684115B2 (en) * | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| CA2839847C (en) * | 2003-06-13 | 2016-03-15 | Masood A. Chowhan | Ophthalmic compositions containing a synergistic combination of two polymers |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| WO2007058935A2 (en) | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US20100234336A1 (en) | 2005-11-14 | 2010-09-16 | Erning Xia | Ophthalmic Compositions |
| US20120028947A1 (en) | 2005-11-14 | 2012-02-02 | Erning Xia | Ophthalmic Compositions |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| CN101966143A (zh) | 2009-07-28 | 2011-02-09 | 胡容峰 | 加替沙星温度及pH敏感眼用凝胶的制备与应用 |
| PH12012501111A1 (en) | 2009-12-03 | 2016-09-09 | Novartis Ag | Carboxyvinyl polymer-containing nanoparticles suspensions |
| KR20140069210A (ko) | 2011-09-22 | 2014-06-09 | 보오슈 앤드 롬 인코포레이팃드 | 안과적 겔 조성물 |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CN111700879A (zh) | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2847207B1 (en) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Fluticasone propionate nanocrystals |
| WO2013169458A1 (en) | 2012-05-11 | 2013-11-14 | Bausch & Lomb Incorporated | Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye |
| BR112014028431B1 (pt) | 2012-05-11 | 2022-01-11 | Activus Pharma Co., Ltd | Nanopó de composto orgânico, método para produzir o mesmo e suspensão |
| MX2015002208A (es) | 2012-08-31 | 2015-05-08 | Bausch & Lomb | Composiciones oftalmicas con acidos grasos omega-3. |
| US20150190407A1 (en) | 2014-01-07 | 2015-07-09 | Insite Vision Incorporated | Methods for treatment of postoperative inflammation with reduced intraocular pressure |
| CN106535943A (zh) | 2014-07-11 | 2017-03-22 | 富士胶片株式会社 | 眼科用水性组合物 |
| NZ728136A (en) | 2014-07-11 | 2017-10-27 | Fujifilm Corp | Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition |
| EP3179982B1 (en) | 2014-07-28 | 2023-07-19 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| EP3470059B1 (en) * | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
-
2016
- 2016-01-26 EP EP18209003.5A patent/EP3470059B1/en active Active
- 2016-01-26 HU HUE23196938A patent/HUE071679T2/hu unknown
- 2016-01-26 KR KR1020177023453A patent/KR102538370B1/ko active Active
- 2016-01-26 EP EP22175139.9A patent/EP4082531B1/en active Active
- 2016-01-26 ES ES22175139T patent/ES2966595T3/es active Active
- 2016-01-26 HU HUE20166312A patent/HUE059639T2/hu unknown
- 2016-01-26 CA CA2975106A patent/CA2975106A1/en not_active Abandoned
- 2016-01-26 JP JP2017558359A patent/JP2018507252A/ja active Pending
- 2016-01-26 PL PL20166312.7T patent/PL3721868T5/pl unknown
- 2016-01-26 MX MX2017009699A patent/MX390671B/es unknown
- 2016-01-26 HU HUE22175139A patent/HUE066045T2/hu unknown
- 2016-01-26 EP EP23196938.7A patent/EP4268850B1/en active Active
- 2016-01-26 SI SI201631905T patent/SI4268850T1/sl unknown
- 2016-01-26 US US15/006,525 patent/US10596107B2/en active Active
- 2016-01-26 CN CN201680016825.XA patent/CN107427464B/zh active Active
- 2016-01-26 PT PT231969387T patent/PT4268850T/pt unknown
- 2016-01-26 HU HUE18209003A patent/HUE048564T2/hu unknown
- 2016-01-26 PL PL18209003T patent/PL3470059T3/pl unknown
- 2016-01-26 ES ES18209003T patent/ES2787039T3/es active Active
- 2016-01-26 PT PT201663127T patent/PT3721868T/pt unknown
- 2016-01-26 PT PT221751399T patent/PT4082531T/pt unknown
- 2016-01-26 AU AU2016211745A patent/AU2016211745A1/en not_active Abandoned
- 2016-01-26 ES ES23196938T patent/ES3031414T3/es active Active
- 2016-01-26 PL PL23196938.7T patent/PL4268850T3/pl unknown
- 2016-01-26 HU HUE16704744A patent/HUE041945T2/hu unknown
- 2016-01-26 PL PL16704744T patent/PL3250185T3/pl unknown
- 2016-01-26 ES ES20166312T patent/ES2924645T5/es active Active
- 2016-01-26 BR BR112017016016-1A patent/BR112017016016B1/pt active IP Right Grant
- 2016-01-26 PL PL22175139.9T patent/PL4082531T3/pl unknown
- 2016-01-26 EP EP20166312.7A patent/EP3721868B2/en active Active
- 2016-01-26 WO PCT/US2016/014872 patent/WO2016123079A1/en not_active Ceased
- 2016-01-26 ES ES16704744T patent/ES2704125T3/es active Active
- 2016-01-26 EP EP16704744.8A patent/EP3250185B1/en not_active Revoked
-
2020
- 2020-03-23 US US16/826,366 patent/US11534395B2/en active Active
-
2021
- 2021-05-12 AU AU2021203027A patent/AU2021203027B2/en active Active
-
2022
- 2022-12-21 US US18/086,286 patent/US12589069B2/en active Active
-
2023
- 2023-10-12 AU AU2023248145A patent/AU2023248145B2/en active Active
-
2025
- 2025-11-24 AU AU2025271194A patent/AU2025271194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507252A5 (enExample) | ||
| Peynshaert et al. | In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye | |
| CL2019003432A1 (es) | Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). | |
| JP2014012746A5 (enExample) | ||
| JP2018090641A5 (enExample) | ||
| CY1124917T1 (el) | Παρασκευη στερεων συμπλοκων κυκλοδεξtρινης για παραδοση οφθαλμικου δραστικου φαρμακευτικου συστατικου | |
| RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
| JP2015025011A5 (enExample) | ||
| MX390671B (es) | Composicion de suspension oftalmica. | |
| JP2018506570A5 (enExample) | ||
| RU2013102030A (ru) | Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции | |
| JP2014527407A5 (enExample) | ||
| WO2012083138A3 (en) | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds | |
| PH12020550009A1 (en) | Pharmaceutical preparation and preparation method therefor | |
| NZ725028A (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| AR089962A1 (es) | Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso | |
| JP2016507526A5 (enExample) | ||
| RU2018112239A (ru) | Фармацевтическая композиция на основе трамадола для офтальмологического применения | |
| JP2020504178A5 (enExample) | ||
| RU2014140885A (ru) | Фармацевтическая композиция ибупрофена и трамадола для офтальмологического применения | |
| JP2016513625A5 (enExample) | ||
| JP2017516770A5 (enExample) | ||
| RU2014125426A (ru) | Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении | |
| JP2019515040A5 (enExample) | ||
| JP2019530729A5 (enExample) |